Royal Drugs And Life Sciences Profile
Key Indicators
- Authorised Capital ₹ 1.50 M
as on 16-11-2024
- Paid Up Capital ₹ 1.50 M
as on 16-11-2024
- Company Age 3 Year, 3 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 8.00 M
as on 16-11-2024
- Revenue 1349.07%
(FY 2023)
- Profit 127.44%
(FY 2023)
- Ebitda 163.63%
(FY 2023)
- Net Worth 5.95%
(FY 2023)
- Total Assets 682.27%
(FY 2023)
About Royal Drugs And Life Sciences
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.50 M and a paid-up capital of Rs 1.50 M.
The company currently has active open charges totaling ₹8.00 M.
Rajinder Singla and Abhishek Singla serve as directors at the Company.
- CIN/LLPIN
U24290HR2021PTC098349
- Company No.
098349
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
08 Oct 2021
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Sonipat, Haryana, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Royal Drugs And Life Sciences?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rajinder Singla  | Director | 08-Oct-2021 | Current |
| Abhishek Singla | Director | 08-Oct-2021 | Current |
Financial Performance of Royal Drugs And Life Sciences.
Royal Drugs And Life Sciences Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 1349.07% increase. The company also saw a substantial improvement in profitability, with a 127.44% increase in profit. The company's net worth moved up by a moderate rise of 5.95%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Royal Drugs And Life Sciences?
Unlock access to Royal Drugs And Life Sciences's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Dhanvantari Life Sciences LimitedActive 11 months 8 daysRajinder Singla and Abhishek Singla are mutual person
- Anshul Enterprises Private LimitedActive 30 years 1 month
Rajinder Singla and Abhishek Singla are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Yes Bank Limited Creation Date: 28 Jul 2023 | ₹8.00 M | Open |
How Many Employees Work at Royal Drugs And Life Sciences?
Royal Drugs And Life Sciences has a workforce of 0 employees as of Apr 04, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Royal Drugs And Life Sciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Royal Drugs And Life Sciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
